The deal, announced June 17, includes a cash offer of $10.50 per share for all outstanding Verve stock. Lilly may also pay as ...

INDIANAPOLIS — Eli Lilly filed lawsuits against compounding pharmacies and an Indianapolis weight loss company over the use of Zepbound and Mounjaro. On April 1, 2025, Lilly filed lawsuits against two ...

INDIANAPOLIS (WISH) — Two Indiana powerhouses have teamed up to accelerate pharmaceutical innovation. Pharmaceutical giant Eli Lilly and Co. on Friday announced plans to invest up to $250 ...

Eli Lilly is investing more in its home state of Indiana, pumping up to $250 million more into an existing collaboration with Purdue University over the next eight years. The boosted pact with the ...

Restoring Indiana’s connection to Europe State leaders ... partnerships that could benefit from the new connection is Eli Lilly and Co. The Indianapolis-based pharmaceutical giant continues ...

“It’s important that Indiana always keep investing in itself ... partnerships that could benefit from the new connection is Eli Lilly and Co. The Indianapolis-based pharmaceutical giant ...

Eli Lilly (NYSE ... is used for drugs sold in China and Europe. Lilly is offsetting that with a $9 billion plant it is building in Indiana with plans to spend another $4.5 billion for a ...

Eli Lilly's oral GLP-1 drug orforglipron showed strong Phase 3 results with 7.9% weight loss and good tolerability, establishing leadership in obesity treatment. Orforglipron offers advantages ...

Eli Lilly stock surged as much as 17% after positive phase-three trial data came out for orforglipron. It found orforglipron, a GLP-1 weight-loss pill, led to significant weight and A1C reductions.

Eli Lilly announced a successful Phase 3 clinical trial of its new GLP-1 weight loss drug, orforglipron, which comes in pill form -- not an injection. This first trial showed weight loss of 7.9% ...

The new route, launching on May 3, will operate four times per week and serve as the only nonstop link between Indiana and Europe ... Companies like Eli Lilly and Cummins are expected to gain ...

Eli Lilly is set to keep growing its revenue at a strong pace in the next five years. The company is likely to add important medicines to its lineup. Eli Lilly's shares look attractive right now.